Skip to content

The study of photodynamic therapy for oral candidiasis

Efficacy and Safety of Methylene Blue Photodynamic Therapy for Oral Candidiasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088856
Enrollment
Unknown
Registered
2024-08-28
Start date
2024-10-10
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral candidiasis

Interventions

Experimental group:methylene blue photodynamic therapy
Control group:Nystatin tablets

Sponsors

Peking University Hospital of Stomatology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Any gender, age >18 years; 2. Clinically diagnosed with oral candida infection; 3. Positive for fungal smear by microscopy or positive for saliva fungal cultures; 4. Female participants of childbearing age in the study with negative pregnancy tests and voluntarily using contraception throughout the course of the trial; 5. Participants in the study voluntarily enroll and a written informed consent form is signed.

Exclusion criteria

Exclusion criteria: 1. Clinically confirmed with other systemic mycoses; 2. Those with a known history of allergy to the test drug, who cannot tolerate it, or who are themselves allergic individuals; 3. Women who are pregnant or breastfeeding; 4. Those who have mental illnesses that prevent them from cooperating well and from evaluating changes regularly; 5. Individuals with hepatic insufficiency (ALT, AST, or TBIL > 1.5 times the upper limit of normal reference values), or clinical manifestations of hepatic disease in the two months prior to the implementation of the study; 6. Those with renal insufficiency (CR > 1.5 times upper limit of normal reference value); 7. Individuals with cardiac insufficiency (e.g., those with ischemic heart failure or a history of congestive heart failure); 8. Those with hematopoietic disorders; 9. Those who have received other systemic antifungal medications within 30 days or topical antifungal medications within 2 weeks prior to the consultation; 10. Those with chronic cutaneous mucocutaneous candidiasis (CMCC); 11. Patients who are HIV-positive; 12. Patients with clinically proven diseases affecting oral salivary secretion or taking medications that affect salivary secretion; 13. Those who have participated in other clinical trials within the last month.

Design outcomes

Primary

MeasureTime frame
Oral pain/burning sensation grading;Mucosal atrophy/erythema grading;Fungal examination;

Countries

China

Contacts

Public ContactPeiru Zhou

Peking University Hospital of Stomatology

zhoupeiru1989@163.com+86 10 8219 5226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 29, 2026